AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05016167 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Replacement every 24 hours
Description: Processing Steps:~1. The monitoring electrodes were not replaced for 24 hours, the electrodes were removed at the end of 24 hours. During the 24-hour follow-up, patients whose electrodes were removed for any reason were excluded from the sample.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd intercostal space (ICA), left 2nd ICA, and midclavicular 5th ICA regions.~3. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~4. The data were recorded.
Study NCT05016167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Replacement every 12 hours
Description: Processing Steps:~1. Monitoring electrodes were removed at the end of the 12th hour. When removing the monitoring electrodes, the area was first wetted using a disinfectant and dried using a sponge after removing the electrodes.~2. Immediately after the drying, skin moisture measurement was made in the right 2nd ICA, left 2nd ICA and midclavicular 5th ICA regions.~3. The skin condition was evaluated from these areas monitored using the skin condition score by the researcher and another independent observer.~4. Monitored again.~5. Monitoring electrodes were removed at the end of the 24th hour. Cleaning and drying were done immediately after removal.~6. Immediately after drying, skin moisture was measured from the monitored areas.~7. The skin condition was evaluated from the areas monitored using the skin condition score by the researcher and another independent observer.~8. The data were recorded.
Study NCT03220581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral for care
Description: referral for addictions support
Study NCT03745391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)
Description: After randomization, a MULTIMODAL CT will be performed to select treatment patient
Study NCT01183572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamins, Folic Acid, and Iron
Description: Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
Study NCT01183572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid and Iron
Description: Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
Study NCT01183572 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Daily oral dose of 0.4 mg folic acid
Study NCT03102424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulator (DW1330)
Description: The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
Study NCT03220581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral for care
Description: referral for addictions support
Study NCT03220581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Description: therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
Study NCT03102424 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham DW1330 device
Description: The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
Study NCT03371394 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04152330 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early stimulation protocol on neuropsychomotor development of children with congenital heart disease
Description: A parenting guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Large Motor and Fine Motor. The duration will be 6 weeks. Parents will participate in 1 individual face-to-face meeting, where they will receive information and clarification on the application of the booklet and will have a mobile communication channel to answer questions throughout the process. Parents will be instructed on the capabilities and limitations of their babies according to the child's congenital heart disease, as well as what is expected within the typical development for this age group and the importance of early stimulation activities in each child in 4 areas of development.
Study NCT03663374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odelepan
Description: Tablets, 125 mg
Study NCT04282967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
Study NCT03663374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
Study NCT03489967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced-hypoglycemia test
Description: Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of \< 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
Study NCT00016744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium 4-Phenylbutyrate (4PBA)
Description: The standard oral adult dose is 20g/day (tablets) for 4 days.
Study NCT00016744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
Study NCT02153463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Counselling
Description: Physical Activity Counselling weekly for 8 weeks
Study NCT00408785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
Study NCT00408785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: sodium chloride 0.9 mg
Study NCT00657748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)
Description: Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
Study NCT02003586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: plant-based ingredient
Study NCT02003586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: No plant-based ingredient
Study NCT04177186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
Study NCT04177186 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Strength training with botulinum toxin
Description: Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
Study NCT02495584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified milk (10µg vitamin D3)
Study NCT04423887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Extremity Resistance Exercise Training
Description: Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval
Study NCT04423887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Resistance Exercise Training
Description: Treadmill walking 5-10 min for warm up Strength training: (80% of 8RM)~3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press, leg extension, Sit to stand squat (mini squats) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)~3 sets 8 reps 10-15 s rep rest interval 1-2 min set rest interval
Study NCT02495584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unfortified milk (placebo)
Study NCT02495584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Unfortified milk (placebo)
Study NCT02495584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10µg vitamin D3 supplement
Study NCT02495584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo supplement
Study NCT02495584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Study NCT00847249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9164
Description: Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
Study NCT00847249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subject will receive a single-dose.
Study NCT00016744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)
Description: Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
Study NCT00016744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
Study NCT01068782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: given orally as capsules
Study NCT03855813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intra rater reliability
Description: Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
Study NCT03855813 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inter rater reliability
Description: Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
Study NCT02529748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participants for Surface Skin Sampling
Description: Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
Study NCT02529748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elemental metallic lead
Description: Consumer product fishing tackle made of elemental lead will be handled by the participants.
Study NCT02529748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tinopal
Description: Tinopal, a fluorescent tracer, will be handled by the participants.
Study NCT03958656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
Study NCT03958656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
Study NCT01364662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: administered orally
Study NCT01879241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Study NCT01879241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a sugar pill manufactured to mimic Rasagiline 1 mg tablet
Study NCT03630575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood and hair collection
Description: At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
Study NCT01375907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotavin
Description: Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
Study NCT04417881 — intervention group
Intervention type: OTHER
Intervention: MEESSI score
Description: MEESSI score in predicting mortality and readmission of patients managed for acute heart failure (AHF) in Emergency Department.
Study NCT00598247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex
Description: Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
Study NCT02074631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamidronate
Description: Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
Study NCT02074631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D
Description: All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
Study NCT02074631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D
Description: All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
Study NCT03958656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: 0.4 mg/kg of Rimiducid intravenous (IV) over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
Study NCT03958656 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells
Description: 0.3x10\^6- 12.0x10\^6 CAR+ T cells per kg of recipient bodyweight one-time dose on day 0
Study NCT02155140 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jejunal feeding
Description: A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
Study NCT00913042 — intervention group
Intervention type: OTHER
Intervention: sample blood
Description: * Early culture~* Bacterial DNA tests in blood
Study NCT04415255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EABPI plus IABPI
Description: If the patient was assigned to EPABI plus IABPI, while the extrapleural space was reached, \~ 15 ml of autologous blood was injected at the extrapleural space through the coaxial needle. Then the central stylet was reinserted and the coaxial needle was advanced into the lung parenchyma with a single puncture. The needle was stopped inside the proximal part of the target and the center needle was removed. A 20-G/16 cm fully-automated biopsy needle was introduced through the 19-G/13.8 cm coaxial needle and specimens were identically obtained. After specimens were collected, the biopsy needle was removed, and immediately the remaining autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
Study NCT04415255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IABPI-alone
Description: If the patient was assigned to IABPI-alone, after collecting the biopsy specimens, immediately the autologous blood (\~5 ml) was slowly injected through the coaxial needle as it was withdrawn through the parenchyma thus sealing the needle tract.
Study NCT03512509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycaemic potato
Description: The Carisma potato variety is used as the low glycaemic index potato.
Study NCT03512509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycaemic potato
Description: The Arizona potato variety is used as the high glycaemic index potato.
Study NCT02769247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Oral naproxen vs placebo
Study NCT02769247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intrauterine lidocaine vs normal saline
Study NCT02769247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: either normal saline or empty oral capsule
Study NCT04423887 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Plan
Description: 2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension
Study NCT04423887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Plan
Description: 2 sets of 10 repetitions/day of~AROM isolated knee extension and knee flexion Isometric isolated knee extension and knee flexion Isometric terminal knee extension Sit to stand squat Isometric knee terminal extension
Study NCT00622700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet Oral administration
Study NCT03845881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
Study NCT03845881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
Study NCT03400579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoRIC® device
Description: The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
Study NCT04811105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: steam ablation
Description: 32 rats have 1 fistula tract .For 16 rats the investigator will use steam ablation to obliterate and 16 rats will be control group
Study NCT02133287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVI® Arsenic trioxide drug eluting stent delivery system
Study NCT02133287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Firebird2® sirolimus eluting stent system
Study NCT02349581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECS block
Description: Ultrasound guided delivery of local anesthetic between the pectoral muscles
Study NCT02349581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT03165279 — intervention group
Intervention type: PROCEDURE
Intervention: Zenith Alpha Abdominal stentgraft
Study NCT04665284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Group A: Empagliflozin 10/25 mg once daily with or without antidiabetic drugs
Study NCT04665284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: Group B: usual care group but without Empagliflozin with adjustment of therapy as the standard of care
Study NCT01433601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Treatment Support (ETS)
Description: An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup.